Literature DB >> 10958084

Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats.

M L Wadenberg1, S Kapur, A Soliman, C Jones, F Vaccarino.   

Abstract

RATIONALE: Human positron emission tomography (PET) shows that striatal dopamine D2 receptor occupancy predicts extrapyramidal side effects (EPS). Patients showed a clinical response with > or = 65% D2 occupancy, but EPS only when D2 occupancy >78%. Catalepsy and the selective suppression of conditioned avoidance response (CAR) are often used as animal models to predict EPS and antipsychotic effect, respectively. However, the quantitative relationship between striatal D2 occupancy and effects in these models is not known.
OBJECTIVES: The present study intended to investigate the relationship between animal catalepsy, suppression of CAR, and D2 receptor blockade using a method of evaluating D2 receptor occupancy similar in principle to that used in patients.
METHODS: In vivo binding of [11C]-raclopride and [3H]-raclopride was compared. Doses of cold raclopride were chosen to provide a D2 occupancy from 0 to 95%. The relationship between dose/time course of catalepsy and D2 occupancy was assessed. Effects of raclopride on conditioned avoidance response (CAR) behavior were tested.
RESULTS: In vivo binding of [11C]-raclopride compared to [3H]-raclopride was virtually the same. Using [3H]-raclopride, cold raclopride (0.01-0.2 mg/kg) produced 16-77% D2 receptor occupancy and no catalepsy. Raclopride (0.5-2 mg/kg) produced 83-95% D2 occupancy and significant catalepsy. Raclopride (2 mg/kg) produced on average 95% and 87% D2 receptor occupancy 1 and 2 h after administration, respectively, and maximum catalepsy. D2 occupancy at 4, 8 and 24 h was on average 58%, 46%, and 4%, respectively. No catalepsy was observed. Raclopride (0.2 mg/kg), estimated at 70-75% D2 occupancy, produced suppression of CAR.
CONCLUSIONS: In vivo D2 occupancy measurements in rats using [3H]-raclopride is analogous to using [11C]-raclopride in human PET scanning. Suppression of CAR occurred at a D2 occupancy of around 70-75%, and catalepsy at D2 occupancy >80%. Results closely resembled human studies where 65-70% D2 occupancy was required for antipsychotic response, while > or = 80% D2 occupancy led to EPS. Brain mechanisms involved in mediation of catalepsy in rats and EPS in humans might indeed be similar. Both suppression of CAR in rats and antipsychotic response in humans might share an underlying construct, i.e. the need for around 70% D2 receptor blockade.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958084     DOI: 10.1007/s002130000466

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

1.  Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses.

Authors:  Devin Mueller; Christian Bravo-Rivera; Gregory J Quirk
Journal:  Biol Psychiatry       Date:  2010-12-01       Impact factor: 13.382

2.  In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.

Authors:  Marie-Bernadette Assié; Hélène Dominguez; Nathalie Consul-Denjean; Adrian Newman-Tancredi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-01       Impact factor: 3.000

3.  The effects of systemic administration of selective antagonists of dopamine D1 and D2/D3 receptors on food-related and defensive (escape responses) conditioned paw-placing responses in cats.

Authors:  V I Maiorov; A G Frolov
Journal:  Neurosci Behav Physiol       Date:  2005-07

4.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Authors:  R Depoortère; L Bardin; A L Auclair; M S Kleven; E Prinssen; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

Review 5.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

6.  Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant.

Authors:  C E Beyer; Q Lin; B Platt; J Malberg; G Hornby; K M Sullivan; D L Smith; T Lock; P J Mitchell; N T Hatzenbuhler; D A Evrard; B L Harrison; R Magolda; M N Pangalos; L E Schechter; S Rosenzweig-Lipson; T H Andree
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

7.  Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in PK/PD of intranasal CNS drugs.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

8.  Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues.

Authors:  Anne-Marie Bédard; Jérôme Maheux; Daniel Lévesque; Anne-Noël Samaha
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

9.  YKP1447, A Novel Potential Atypical Antipsychotic Agent.

Authors:  Seon Min Dong; Yong Gil Kim; Joon Heo; Mi Kyung Ji; Jeong Woo Cho; Byong Sung Kwak
Journal:  Korean J Physiol Pharmacol       Date:  2009-04-30       Impact factor: 2.016

10.  ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.

Authors:  Robert E Davis; Kimberly E Vanover; Yun Zhou; James R Brašić; Maria Guevara; Blanca Bisuna; Weiguo Ye; Vanessa Raymont; William Willis; Anil Kumar; Lorena Gapasin; D Ronald Goldwater; Sharon Mates; Dean F Wong
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.